Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin

Table 4

The incidence rate of adverse reactions in AML patients following intravenous administration of cytarabine supplemented with either idarubicin or daunorubicin.

Group	Case	Nausea and vomiting (n, %)	Myelosuppression (n, %)	Infection (n, %)	Leukopenia (n, %)	Total incidence (n, %)
Control group	44	12 (27.27)	5 (11.36)	3 (6.82)	7 (15.91)	27 (61.36)
Study group	44	7 (15.91)	2 (4.55)	2 (4.55)	4 (9.09)	15 (34.09)
t						16.675
						0.018